Mainz Biomed organizes HALLO DOC! Event to showcase inventions in colorectal cancer treatment
BERKELEY, USA – MANZ, Germany – March 19, 2024 — Mainz Biomed N. V. (NASDAQ: MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetic diagnostic responses for early cancer detection, will host the HALLO DOC Event, reporting on colorectal cancer, cutting-edge research, new treatment modalities, and holistic healing approaches. This event will take place on March 20, 2024 in Berlin, Germany, as part of Colorectal Cancer Awareness Month.
HELLO DOC! comes at a critical time, as the occurrence of colorectal cancer is increasing alarmingly, especially among young people, highlighting the need for effective prevention, early detection, and prevention of recurrence. Mainz Biomed organized this occasion to highlight new diagnostic methods, the importance of comprehensive healing, and the latest advances in colorectal cancer research.
Presence:
Mainz Biomed is at the forefront of the search for commercialized, molecular genetic diagnostic answers for life-threatening diseases. Its leading product, ColoAlert®, offers an accurate, non-invasive, and easy-to-use at-home screening test for colorectal cancer, marking a significant advance in prevention and early detection strategies.
Guido Baechler, CEO of Mainz Biomed, commented: “As we witness a trend of concern over the past two decades (an increase in colorectal cancer cases among younger populations), it is imperative to find cutting-edge answers and holistic approaches to fight this. The HALLO DOC event represents our commitment to advancing the debate on prevention, early detection and treatment by showcasing the perspectives of some of the most esteemed professionals in the field.
Please refer to Mainz Biomed’s official online investor page in mainzbiomed. com/investors/ for more information.
About ColoAlert®
Mainz Biomed’s flagship product, ColoAlert®, offers maximum sensitivity and specificity in an easy-to-use, at-home colorectal cancer (CRC) screening kit. This non-invasive verification may be indicative of the tumors we decide on by analyzing tumor DNA, offering greater early detection than fecal occult blood (FOBT) checks. Based on PCR technology, ColoAlert® detects more cases of colorectal cancer than other stool controls and allows for prior diagnosis (Dollinger et al. , 2018). The product is available comercialmente. se decided in EU countries through a network of leading independent laboratories, corporate fitness systems and through direct sales. To obtain marketing approval in the U. S. In the U. S. , ColoAlert® will be evaluated in the FDA’s “ReconAAsense” registration trial. Once approved in the U. S. , the company’s business strategy is to identify scalable distribution through a collaborative partnership program with regional and national laboratory service providers across the country.
About Colorectal Cancer
Colorectal cancer (CRC) is the third most common cancer worldwide, with more than 1. 9 million new cases reported in 2020, according to the International Fund for Research on World Cancer. The U. S. Preventive Services Task Forcerecommends that screening with stool DNA tests such as ColoAlert ® should be done once every 3 years starting at age 45. Each year in the United States, 16. 6 million colonoscopies are performed. However, about one-third of U. S. citizens between the ages of 50 and 75 have never been screened for colon cancer. This test hole represents an overall market opportunity of more than $4. 0 billion in the United States.
Mainz Biomed develops commercially available molecular genetic diagnostic responses for life-threatening diseases. The company’s core product is ColoAlert®, an accurate, non-invasive, and easy-to-use colorectal cancer early detection diagnostic monitor based on a real-time multiplex polymerase chain. Reaction detection (PCR) of molecular and genetic biomarkers in stool samples. ColoAlert® is recently announced in Europa. La company is recently conducting a major clinical study with the FDA to gain regulatory approval in the United States. Mainz Biomed’s product applicant portfolio also includes PancAlert, an early-stage pancreatic cancer screening test. For more information, visit mainzbiomed. com.
For Media Inquiries
Forward-Looking Statements
Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements would likely be made known by the use of words such as ” anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook” and “project” and other similar expressions that expect or imply long-term events or trends or that are not statements of long-standing matters. These forward-looking statements reflect existing research based on existing data and are subject to various hazards and uncertainties. Accordingly, caution should be exercised in relying on forward-looking statements. Due to known and unknown hazards, actual effects would likely differ materially from the following points, among others, may also cause actual effects to differ materially from those described in such forward-looking statements: (i) failure to achieve projected progression and similar objectives ; (ii) adjustments to applicable legislation or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its existing or expected markets; and (iv) the other dangers and uncertainties described herein, as well as the dangers and uncertainties discussed from time to time in other reports and other public documents filed with the Securities and Exchange Commission (the “SEC”) through the Company. Additional data relating to those and other items that could possibly have an effect on the Company’s expectations and projections can be discovered in its initial filings with the SEC, adding to its Annual Report on Form 20-F filed on April 7, 2023 The Company’s SEC filings are publicly available at the SEC’s online website at www. sec. gov. Any forward-looking statement we make in this press release is based solely on Mainz Biomed’s existing data and speaks only as of the date on which it is made. Mainz Biomed undertakes no legal responsibility to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new data, long-term developments or otherwise, unless we do so. requires the law.